We are live on ! Find out more
LYRA

LYRA THERAPEUTICS INC

Delisted

LYRA was delisted on the 16th of March, 2026.

78 hedge funds and large institutions have $283M invested in LYRA THERAPEUTICS INC in 2024 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 29 increasing their positions, 12 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

23,225% more call options, than puts

Call options by funds: $1.87M | Put options by funds: $8K

257% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 7

142% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 12

50% more funds holding in top 10

Funds holding in top 10: 23 (+1)

30% more funds holding

Funds holding: 6078 (+18)

28% more capital invested

Capital invested by funds: $222M → $283M (+$61.4M)

0.09% less ownership

Funds ownership: 1.61%1.53% (-0.09%)

Holders
78
Holders Change
+18
Holders Change %
+30%
% of All Funds
1.12%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.04%
New
25
Increased
29
Reduced
12
Closed
7
Calls
$1.87M
Puts
$8K
Net Calls
+$1.86M
Net Calls Change
+$616K
Name Holding Trade Value Shares
Change
Change in
Stake
Hudson Bay Capital Management
26
Hudson Bay Capital Management
Connecticut
$1.55M +$1.33M +5,000 New
BFM
27
Boothbay Fund Management
New York
$1.45M -$92.2K -346 -7%
Dimensional Fund Advisors
28
Dimensional Fund Advisors
Texas
$1.19M +$418K +1,567 +70%
Two Sigma Investments
29
Two Sigma Investments
New York
$1.14M +$273K +1,023 +39%
ACP
30
Acuta Capital Partners
California
$1.08M +$923K +3,466 New
Bank of America
31
Bank of America
North Carolina
$993K +$79.4K +298 +10%
Jane Street
32
Jane Street
New York
$981K +$423K +1,589 +102%
BlackRock
33
BlackRock
New York
$945K +$219K +822 +37%
SCM
34
Superstring Capital Management
New York
$904K +$774K +2,906 New
Two Sigma Advisers
35
Two Sigma Advisers
New York
$895K +$497K +1,864 +184%
Qube Research & Technologies (QRT)
36
Qube Research & Technologies (QRT)
United Kingdom
$820K +$407K +1,529 +138%
State Street
37
State Street
Massachusetts
$785K +$90.6K +340 +16%
CC
38
Clearline Capital
New York
$741K
Citigroup
39
Citigroup
New York
$739K -$29.6K -111 -4%
JP Morgan Chase
40
JP Morgan Chase
New York
$680K +$406K +1,525 +230%
HF
41
HRT Financial
New York
$612K +$525K +1,971 New
Man Group
42
Man Group
United Kingdom
$562K +$279K +1,046 +138%
BCM
43
Bridgeway Capital Management
Texas
$540K -$293K -1,100 -39%
MTIM
44
Marathon Trading Investment Management
Pennsylvania
$417K +$357K +1,340 New
Morgan Stanley
45
Morgan Stanley
New York
$401K +$343K +1,288 New
Northern Trust
46
Northern Trust
Illinois
$376K -$5.59K -21 -2%
Renaissance Technologies
47
Renaissance Technologies
New York
$317K +$37.3K +140 +16%
Cambridge Investment Research Advisors
48
Cambridge Investment Research Advisors
Iowa
$259K +$221K +831 New
Barclays
49
Barclays
United Kingdom
$204K
ECM
50
ExodusPoint Capital Management
New York
$200K +$16.3K +61 +10%

LYRA Hedge Fund Activity: Q1 2024 in Review

78 of the 6,945 institutional investors tracked by Wall St. Rank reported a position in LYRA THERAPEUTICS INC (LYRA) for Q1 2024, worth a combined $283M — up 28% from $222M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new LYRA positions and 7 closed out — a net gain of 18 holders — while 29 added to existing stakes and 12 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $7.88M. The largest seller was Vestal Point Capital, cutting an estimated $11.7M.

  • 78 institutional investors held LYRA THERAPEUTICS INC (LYRA) as of Q1 2024, up from 60 in Q4 2023.
  • Funds reported $283M of LYRA THERAPEUTICS INC stock for Q1 2024, up 28% quarter-over-quarter.
  • 25 funds opened new LYRA THERAPEUTICS INC positions in Q1 2024 and 7 closed out, a net change of +18 holders.
  • The largest LYRA THERAPEUTICS INC buyer in Q1 2024 was Citadel Advisors, an estimated $7.88M added.
  • The largest LYRA THERAPEUTICS INC seller in Q1 2024 was Vestal Point Capital, an estimated $11.7M sold.

Based on aggregated 13F filings for Q1 2024.